JPMorgan Chase & Co. set a €85.80 ($99.77) price objective on Fresenius Medical Care AG & Co. KGaA (ETR:FME) in a report published on Thursday morning, Borsen Zeitung reports. The brokerage currently has a buy rating on the stock.

Other analysts have also issued reports about the stock. Nord/LB set a €92.00 ($106.98) price target on shares of Fresenius Medical Care AG & Co. KGaA and gave the company a buy rating in a research report on Friday, May 3rd. HSBC set a €101.00 ($117.44) price target on shares of Grenke and gave the company a buy rating in a research report on Thursday, April 25th. Kepler Capital Markets set a €80.00 ($93.02) price target on shares of Fresenius Medical Care AG & Co. KGaA and gave the company a buy rating in a research report on Thursday, May 2nd. Independent Research set a €74.00 ($86.05) price target on shares of Fresenius Medical Care AG & Co. KGaA and gave the company a neutral rating in a research report on Monday, June 17th. Finally, Goldman Sachs Group set a $13.00 price target on shares of Ford Motor and gave the company a buy rating in a research report on Thursday, June 13th. Seven research analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the stock. Fresenius Medical Care AG & Co. KGaA currently has an average rating of Buy and an average target price of €82.57 ($96.01).

FME stock opened at €69.70 ($81.05) on Thursday. The stock has a market capitalization of $21.28 billion and a price-to-earnings ratio of 10.85. The firm’s 50-day moving average price is €68.10. Fresenius Medical Care AG & Co. KGaA has a one year low of €55.44 ($64.47) and a one year high of €91.74 ($106.67). The company has a current ratio of 1.02, a quick ratio of 0.67 and a debt-to-equity ratio of 100.05.

Fresenius Medical Care AG & Co. KGaA Company Profile

Fresenius Medical Care AG & Co KGaA, a kidney dialysis company, provides dialysis care and related services, and other health care services in Germany, the United States, and internationally. It offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.

Recommended Story: How is a management fee different from a performance fee?

Analyst Recommendations for Fresenius Medical Care AG & Co. KGaA (ETR:FME)

Receive News & Ratings for Fresenius Medical Care AG & Co. KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fresenius Medical Care AG & Co. KGaA and related companies with MarketBeat.com's FREE daily email newsletter.